Effect of baseline characteristics on prostate cancer rates and risk reduction in the Reduction by Dutasteride of prostate Cancer Events REDUCE) trial

被引：0
|
作者：
Andriole, G. [1 ]
Brawley, O. [2 ]
Gomella, L. [3 ]
Marberger, M. [4 ]
Montorsi, F. [5 ]
Pettaway, C. [6 ]
Teloken, C. [7 ]
Tammela, T. [8 ]
Tindall, D. [9 ]
Rittmaster, R. [10 ]
机构：
[1] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[4] Univ Vienna, Dept Urol, Vienna, Austria
[5] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Fed Med Sch FFCMPA, Dept Urol, Alegre, Brazil
[8] Tampere Univ Hosp, Div Urol, Tampere, Finland
[9] Mayo Clin & Mayo Grad Sch Med, Dept Urol, Rochester, MN USA
[10] GlaxoSmithKline Inc, Urol Med Dev, Res Triangle Pk, NC USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71384-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：407 / 408
页数：2
相关论文
共 50 条
  • [1] EFFECT OF BASELINE PROSTATE CANCER RISK ON DUTASTERIDE EFFICACY IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY
    Marberger, M.
    Pettaway, C.
    Tammela, T.
    Tindall, D. J.
    Teloken, C.
    Wilson, T. H.
    Castro, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 300 - 301
  • [2] Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial
    Andriole, G
    Bostwick, D
    Brawley, O
    Gomella, L
    Tindall, D
    Breed, S
    Somerville, M
    Rittmaster, R
    JOURNAL OF UROLOGY, 2004, 172 (04): : 1314 - 1317
  • [3] The influence of unscheduled biopsies on prostate cancer detection in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial
    Andriole, G. L.
    Pettaway, C.
    Tindall, D. J.
    Rittmaster, R. S.
    Wilson, T. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial
    Roehrborn, Claus G.
    Nickel, J. Curtis
    Andriole, Gerald L.
    Gagnier, R. Paul
    Black, Libby
    Wilson, Timothy H.
    Rittmaster, Roger S.
    UROLOGY, 2011, 78 (03) : 641 - 646
  • [5] THE INFLUENCE OF UNSCHEDULED BIOPSIES ON PROSTATE CANCER DETECTION IN THE REDUCE (REDUCTION OF DUTASTERIDE IN CANCER EVENTS) TRIAL
    Marberger, M.
    Montorsi, F.
    Bostwick, D.
    Fowler, I. L.
    Wilson, T. H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 217 - 217
  • [6] EFFECT OF BASELINE CHARACTERISTICS ON RELATIVE RISK OF PROSTATE CANCER PROGRESSION IN THE REDUCTION BY DUTASTERIDE OF CLINICAL PROGRESSION EVENTS IN EXPECTANT MANAGEMENT (REDEM) TRIAL
    Fleshner, N. E.
    Lucia, M. S.
    Egerdie, B.
    Black, L.
    Melich, K.
    Nandy, I
    Rittmaster, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 51 - 52
  • [7] REDUCTION IN SURGICAL AND NON-SURGICAL INTERVENTIONS FOR PROSTATE CANCER WITH DUTASTERIDE TREATMENT IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY
    Rittmaster, R.
    Montorsi, F.
    Marberger, M.
    Roehrborn, C.
    Andriole, G.
    Somerville, M.
    Castro, R.
    Fueyo, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 275 - 275
  • [8] Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study.
    Brawley, O. W.
    Andriole, G. L.
    Teloken, C.
    Somerville, M. C.
    Gagnier, R. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Serum Testosterone and Dihydrotestosterone and Prostate Cancer Risk in the Placebo Arm of the Reduction by Dutasteride of Prostate Cancer Events Trial
    Muller, Roberto L.
    Gerber, Leah
    Moreira, Daniel M.
    Andriole, Gerald
    Castro-Santamaria, Ramiro
    Freedland, Stephen J.
    EUROPEAN UROLOGY, 2012, 62 (05) : 757 - 764
  • [10] Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial EDITORIAL COMMENT
    Madersbacher, Stephan
    UROLOGY, 2011, 78 (03) : 646 - 647
12345